CymitQuimica logo

CAS 338992-00-0

:

Vandetanib

Description:
Vandetanib is a small molecule tyrosine kinase inhibitor primarily used in the treatment of certain types of cancer, particularly medullary thyroid carcinoma. Its mechanism of action involves the inhibition of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) kinase, which play crucial roles in tumor growth and angiogenesis. Vandetanib is typically administered orally and is characterized by its ability to interfere with tumor cell proliferation and vascularization. The compound has a relatively complex chemical structure, which contributes to its pharmacological properties. Common side effects associated with its use may include diarrhea, hypertension, and skin rashes, reflecting its impact on normal cellular processes. Vandetanib is classified as an antineoplastic agent and is subject to specific regulatory guidelines regarding its use and monitoring due to potential adverse effects. Its development represents a significant advancement in targeted cancer therapies, offering a more tailored approach to treatment.
Formula:C22H24BrFN4O2
InChI:InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)
InChI key:InChIKey=UHTHHESEBZOYNR-UHFFFAOYSA-N
SMILES:N(C=1C2=C(C=C(OCC3CCN(C)CC3)C(OC)=C2)N=CN1)C4=C(F)C=C(Br)C=C4
Synonyms:
  • N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine
  • 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline
  • Vandetanib
  • 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-
  • ZD 6474
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 1 products.